CompletedNCT02634346

A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)

Researchers compared ALK3831, Olanzapine and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

Medication studyAges 18–70Multiple countries

The study in practice

Understand this study

Researchers compared ALK3831, Olanzapine and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Listed locations: Little Rock and 30 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateStarted: December 2015

Recruitment status: Completed
Enrollment listed in the registry: 403
Sponsor: Alkermes, Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, Bulgaria, Serbia, ...
Age range: From 18 Years to 70 Years
Official registry ID: NCT02634346
Official title: Show the full official title
A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia

Completed

Little Rock, United States · Springdale, United States · Culver City, United States

28 more locations

FAQ

What did researchers investigate?

Researchers compared ALK3831, Olanzapine and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

Who is behind this study?

The study sponsor is Alkermes, Inc.

Did this study involve medication?

Yes. The study involved medication, including ALK3831, Olanzapine and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 70 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.